A 56-year-old patient with well-controlled type 2 diabetes and hypertension comes to the APRN for routine follow-up. His blood pressure is controlled with lisinopril 40 mg/day, but his albumin-to-creatinine ratio is 75 mg/g. The patient's records show that his albuminuria is getting progressively worse. The APRN wonders whether the combination of an angiotensin-converting enzyme (ACE) inhibitor and an ARB would slow the decline of renal function, and whether the combination would reduce the patient’s cardiovascular risk. What should the APRN implement in order to address the patient's albuminuria?